Position
Fidelity in Nuvectis Pharma, Inc.
Back to the book · All holders of NVCT
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $80.7K$7.73 → $18.39
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 7.21K | $54.4K | — | — | — | 0.0% |
| Q1 2026 | 7.57K | $58.5K | $7.73 | $1.3K | $2.77K | 0.0% |
| Q2 2026 | 8.06K | $148.2K | $18.39 | $80.7K | $9.07K | 0.0% |